Research · Peptide synopsis

KPV — α-MSH C-terminal anti-inflammatory tripeptide research

Wellness Labs Editorial·26 May 2026·8 min read

KPV is the C-terminal three amino acids of α-melanocyte-stimulating hormone. The parent peptide binds melanocortin receptors and drives a long list of pigmentation, appetite, and inflammatory programs. The tripeptide does not appreciably bind those receptors at all — and yet retains a large fraction of the parent peptide’s anti-inflammatory activity. That is the puzzle the published research has been working on for the better part of three decades.

What KPV actually is

KPV is a synthetic tripeptide: Lysine-Proline-Valine. The sequence is the final three residues of α-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid endogenous melanocortin peptide cleaved from pro-opiomelanocortin in the pituitary. α-MSH itself is the canonical agonist for the melanocortin-1 receptor (MC1R) on melanocytes and has well-characterised roles in pigmentation, energy balance, and inflammatory signalling.

Early structure-activity work in the 1980s and 1990s asked a simple question: how much of α-MSH’s anti-inflammatory profile is carried by which fragment? When the molecule was truncated and tested across the inflammation literature, the C-terminal tripeptide — KPV — repeatedly came back as the smallest fragment that retained a meaningful proportion of the parent activity. The 2008 consolidated review by Brzoska, Luger and colleagues in Endocrine Reviews remains the field’s standard reference for this mapping [1].

Three amino acids is a very small molecule by peptide standards. KPV has a molecular weight of ~342 Da, is relatively peptidase-resistant compared to most short peptides, and unlike most peptide drugs can survive oral administration in usable amounts — which is part of why the IBD literature has been able to use oral and rectal dosing routes in animal models.

What the mechanism research shows

The strongest distinguishing feature of the KPV literature is that the mechanism is largely receptor-independent. The parent peptide α-MSH binds melanocortin receptors (MC1R-MC5R) with high affinity; KPV does not. The published literature points to two non-receptor pathways:

Intracellular NF-κB pathway interference. Cell-line work has reported that KPV enters cells, traffics to the nucleus, and interferes with NF-κB transcription-factor activation downstream of pro-inflammatory stimuli (TNF-α, IL-1β, LPS). Mandrika and colleagues published one of the earliest cell-line demonstrations of this effect using MC-receptor-deficient lines, ruling out a receptor-mediated explanation [2].
PepT1-mediated intestinal uptake. The intestinal di/tripeptide transporter PepT1 is upregulated in inflamed colonic epithelium. Work from the Merlin lab at Emory has shown that KPV is taken up via PepT1 into intestinal epithelial cells and immune cells of the lamina propria, producing localised anti-inflammatory signalling in IBD models [3]. This is the proposed reason oral KPV reaches functional concentrations at the inflamed gut wall despite being a small peptide.

A three-amino-acid peptide that retains a substantial fraction of the parent’s activity, via a different mechanism than the parent uses, is genuinely interesting biology. It is also why the popular framing of KPV as “α-MSH lite” is misleading — the C-terminal fragment works differently from the parent.

What the preclinical animal-model data shows

The published KPV literature concentrates in three injury-model areas:

Inflammatory bowel disease (IBD). Dextran-sodium-sulphate (DSS) and trinitrobenzenesulphonic-acid (TNBS) colitis models in mice are the workhorses. Both oral and rectally-administered KPV have been reported to reduce colonic inflammation scores, weight-loss, and pro-inflammatory cytokine expression in these models. The 2008 Gastroenterology paper from Dalmasso et al. is the most-cited entry point to this line of work [3].
Dermal and contact-dermatitis models. Mouse contact-hypersensitivity models (oxazolone, TPA) and ovalbumin-induced dermal inflammation have shown reductions in oedema and cytokine markers under topical or subcutaneous KPV. This is the line of research that supports the dermatology-research interest in the compound.
Cytokine-suppression assays. Across multiple immune-cell preparations (monocytes, dendritic cells, T cells), KPV exposure has been reported to dampen the production of TNF-α, IL-1β, IL-6, and IFN-γ in response to inflammatory stimuli, consistent with the proposed NF-κB pathway mechanism.

The pattern across this preclinical literature is similar in shape to the BPC-157 picture: consistent positive signals at the tissue and cytokine-marker level across a wide range of inflammation models, primarily reported by a relatively small number of laboratories, with the IBD work being the most extensively replicated.

The human-trial gap

ClinicalTrials.gov has essentially no completed phase-2 or phase-3 randomised controlled trials of KPV. There is a small published clinical literature on related α-MSH analogues — most notably afamelanotide (an MC1R agonist, an entirely different compound class) — but the body of human-RCT data on KPV itself is not there.

This is not surprising given the regulatory pathway: KPV has never been advanced as a commercial drug-development candidate by a major pharmaceutical company, and the preclinical work has stayed in academic hands. The result is the standard pattern for research peptides — strong preclinical signal, no formal clinical translation, sold globally as a research-grade chemical.

Two consequences follow. First, any specific human-condition claim (ulcerative-colitis outcomes in patients, eczema improvement rates in patients) is extrapolating from animal data — the human RCT data to support those claims does not exist in peer-reviewed form. Second, the compound is not approved as a medicine by the FDA, EMA, or the UAE Ministry of Health, and is sold for non-clinical research investigation only.

The UAE research-supply landscape

KPV is supplied in the UAE as a lyophilised powder (most commonly 10 mg per vial) by a small number of research-supply vendors. The underlying chemistry is straightforward solid-phase peptide synthesis — a three-residue peptide is one of the easier syntheses in the category — but purity-control and analytical verification still vary considerably across vendors.

If you are evaluating KPV for a research programme, you can browse our research-grade KPV consultation — every vial dispatched from Wellness Labs ships with batch-numbered HPLC documentation. The chat consultation will surface the COA on request.

Open questions

The questions the preclinical literature has NOT yet answered include:

Human pharmacokinetics. The oral bioavailability, distribution, and metabolism of KPV in humans have not been formally characterised in published peer-reviewed literature.
Dose-response specificity. Animal-model doses span several orders of magnitude, and the dose-response curves are not always monotonic. Translation to human dosing is therefore extrapolated, not empirical.
Selectivity of the NF-κB interference. The pathway-level mechanism is consistent across reports, but the molecular target inside cells (the exact protein KPV binds to interrupt NF-κB activation) is not definitively identified.
Receptor-independence at all doses. At very high doses, low-affinity binding to melanocortin receptors cannot be entirely ruled out, and a small minority of papers argue for residual MC-receptor involvement.